These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 36094573)

  • 1. GARFIELD-AF: risk profiles, treatment patterns and 2-year outcomes in patients with atrial fibrillation in Germany, Austria and Switzerland (DACH) compared to 32 countries in other regions worldwide.
    Haas S; Camm JA; Harald D; Steffel J; Virdone S; Pieper K; Brodmann M; Schellong S; Misselwitz F; Kayani G; Kakkar AK;
    Clin Res Cardiol; 2023 Jun; 112(6):759-771. PubMed ID: 36094573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk Profile and 1-Year Outcome of Newly Diagnosed Atrial Fibrillation in Japan　- Insights From GARFIELD-AF.
    Koretsune Y; Etoh T; Katsuda Y; Suetsugu T; Kumeda K; Sakuma I; Eshima K; Shibuya M; Ando SI; Yokota N; Goto S; Pieper KS; Allu J; Kakkar AK;
    Circ J; 2018 Dec; 83(1):67-74. PubMed ID: 30518731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Why are outcomes different for registry patients enrolled prospectively and retrospectively? Insights from the global anticoagulant registry in the FIELD-Atrial Fibrillation (GARFIELD-AF).
    Fox KAA; Accetta G; Pieper KS; Bassand JP; Camm AJ; Fitzmaurice DA; Kayani G; Kakkar AK;
    Eur Heart J Qual Care Clin Outcomes; 2018 Jan; 4(1):27-35. PubMed ID: 28950344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.
    Sawhney JP; Kothiwale VA; Bisne V; Durgaprasad R; Jadhav P; Chopda M; Vanajakshamma V; Meena R; Vijayaraghavan G; Chawla K; Allu J; Pieper KS; John Camm A; Kakkar AK;
    Indian Heart J; 2018; 70(6):828-835. PubMed ID: 30580852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment patterns in anticoagulant therapy in patients with newly diagnosed atrial fibrillation in Belgium: results from the GARFIELD-AF registry.
    Cools F; Wollaert B; Vervoort G; Verstraete S; Voet J; Hermans K; Heyse A; De Wolf A; Hollanders G; Boussy T; Anné W; Vercammen J; Faes D; Beutels M; Mairesse G; Purnode P; Blankoff I; Vandergoten P; Capiau L; Allu J; Bassand JP; Kayani G;
    Acta Cardiol; 2019 Aug; 74(4):309-318. PubMed ID: 30369290
    [No Abstract]   [Full Text] [Related]  

  • 6. International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries.
    Steinberg BA; Gao H; Shrader P; Pieper K; Thomas L; Camm AJ; Ezekowitz MD; Fonarow GC; Gersh BJ; Goldhaber S; Haas S; Hacke W; Kowey PR; Ansell J; Mahaffey KW; Naccarelli G; Reiffel JA; Turpie A; Verheugt F; Piccini JP; Kakkar A; Peterson ED; Fox KAA; ;
    Am Heart J; 2017 Dec; 194():132-140. PubMed ID: 29223431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of Oral Anticoagulation in Atrial Fibrillation Patients With or Without Comorbid Vascular Disease: Insights From the GARFIELD-AF Registry.
    Verheugt FWA; Fox KAA; Virdone S; Ambrosio G; Gersh BJ; Haas S; Pieper KS; Kayani G; Camm AJ; Parkhomenko A; Misselwitz F; Ragy H; Ten Cate H; Keltai M; Kakkar AK;
    Am J Med; 2023 Dec; 136(12):1187-1195.e15. PubMed ID: 37704071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vitamin K antagonist control in patients with atrial fibrillation in Asia compared with other regions of the world: Real-world data from the GARFIELD-AF registry.
    Oh S; Goto S; Accetta G; Angchaisuksiri P; Camm AJ; Cools F; Haas S; Kayani G; Koretsune Y; Lim TW; Misselwitz F; van Eickels M; Kakkar AK;
    Int J Cardiol; 2016 Nov; 223():543-547. PubMed ID: 27552578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).
    Steinberg BA; Shrader P; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Hylek E; Kowey PR; Mahaffey KW; O'Brien EC; Singer DE; Peterson ED; Piccini JP;
    Am Heart J; 2017 Jul; 189():40-47. PubMed ID: 28625380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risks associated with discontinuation of oral anticoagulation in newly diagnosed patients with atrial fibrillation: Results from the GARFIELD-AF Registry.
    Cools F; Johnson D; Camm AJ; Bassand JP; Verheugt FWA; Yang S; Tsiatis A; Fitzmaurice DA; Goldhaber SZ; Kayani G; Goto S; Haas S; Misselwitz F; Turpie AGG; Fox KAA; Pieper KS; Kakkar AK;
    J Thromb Haemost; 2021 Sep; 19(9):2322-2334. PubMed ID: 34060704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management and 1-Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD - AF Registry.
    Goto S; Angchaisuksiri P; Bassand JP; Camm AJ; Dominguez H; Illingworth L; Gibbs H; Goldhaber SZ; Goto S; Jing ZC; Haas S; Kayani G; Koretsune Y; Lim TW; Oh S; Sawhney JPS; Turpie AGG; van Eickels M; Verheugt FWA; Kakkar AK;
    J Am Heart Assoc; 2019 Feb; 8(3):e010510. PubMed ID: 30717616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GARFIELD-AF: a worldwide prospective registry of patients with atrial fibrillation at risk of stroke.
    Bassand JP; Apenteng PN; Atar D; Camm AJ; Cools F; Corbalan R; Fitzmaurice DA; Fox KA; Goto S; Haas S; Hacke W; Jerjes-Sanchez C; Koretsune Y; Heuzey JL; Sawhney JP; Oh S; Stępińska J; Cate VT; Verheugt FW; Kayani G; Pieper KS; Kakkar AK; Garfield-Af Investigators FT
    Future Cardiol; 2021 Jan; 17(1):19-38. PubMed ID: 32696663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Middle East Treatment Strategies and Clinical Outcomes in Patients with Atrial Fibrillation: One-Year Follow-up Data from Garfield-AF Study.
    Sayin BY; Al Mahmeed W; Ragy HI; Elbahry A; Virdone S; Kakkar AK; Ersanlı M; Oto A
    Adv Ther; 2021 May; 38(5):2391-2405. PubMed ID: 33772428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF.
    Haas S; Camm AJ; Bassand JP; Angchaisuksiri P; Cools F; Corbalan R; Gibbs H; Jacobson B; Koretsune Y; Mantovani LG; Misselwitz F; Panchenko E; Ragy HI; Stepinska J; Turpie AG; Sawhney JP; Steffel J; Lim TW; Pieper KS; Virdone S; Verheugt FW; Kakkar AK;
    Am Heart J; 2019 Jul; 213():35-46. PubMed ID: 31128503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy.
    De Caterina R; Brüggenjürgen B; Darius H; Köhler S; Lucerna M; Pecen L; Renda G; Schilling RJ; Schliephacke T; Zamorano JL; Le Heuzey JY; Kirchhof P
    Arch Cardiovasc Dis; 2018 Feb; 111(2):74-84. PubMed ID: 28942115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stroke prevention, 1-year clinical outcomes and healthcare resource utilization in patients with atrial fibrillation in France: Data from the GARFIELD-AF registry.
    Le Heuzey JY; Bassand JP; Berneau JB; Cozzolino P; D'Angiolella L; Doucet B; Mantovani LG; Martelet M; Mouallem J; Muller JJ; Pieper K;
    Arch Cardiovasc Dis; 2018 Dec; 111(12):749-757. PubMed ID: 29861295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Characteristics, Oral Anticoagulation Patterns, and Outcomes of Medicaid Patients With Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF I) Registry.
    O'Brien EC; Kim S; Thomas L; Fonarow GC; Kowey PR; Mahaffey KW; Gersh BJ; Piccini JP; Peterson ED
    J Am Heart Assoc; 2016 May; 5(5):. PubMed ID: 27146448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GARFIELD-AF risk score for mortality, stroke, and bleeding within 2 years in patients with atrial fibrillation.
    Fox KAA; Virdone S; Pieper KS; Bassand JP; Camm AJ; Fitzmaurice DA; Goldhaber SZ; Goto S; Haas S; Kayani G; Oto A; Misselwitz F; Piccini JP; Dalgaard F; Turpie AGG; Verheugt FWA; Kakkar AK;
    Eur Heart J Qual Care Clin Outcomes; 2022 Mar; 8(2):214-227. PubMed ID: 33892489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk profile, antithrombotic treatment and clinical outcomes of patients in Nordic countries with atrial fibrillation - results from the GARFIELD-AF registry.
    Pope MK; Atar D; Svilaas A; Hole T; Nielsen JD; Hintze U; Crisby M; Raatikainen P; Airaksinen KEJ; Virdone S; Pieper K; Kayani G; Le Heuzey JY; Steffel J; Stepinska J; Bassand JP; Camm AJ;
    Ann Med; 2021 Dec; 53(1):485-494. PubMed ID: 33818226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stroke prevention in atrial fibrillation patients in Poland and other European countries: insights from the GARFIELD-AF registry.
    Stępińska J; Kremis E; Konopka A; Wożakowska-Kapłon B; Ruszkowski P; Kukla P; Kayani G
    Kardiol Pol; 2016; 74(4):362-71. PubMed ID: 26365937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.